4/A: Xtant Medical Holdings Executive Adjusts Stock Awards in Amended SEC Filing

An amended SEC filing reveals an adjustment to the number of shares issuable to Xtant Medical Holdings' Chief Operations Officer, Mark A. Schallenberger, under deferred stock unit awards.

Summary

• This is an amended SEC Form 4 filing by Mark A. Schallenberger, Chief Operations Officer of Xtant Medical Holdings, Inc.
• The amendment adjusts the number of shares issuable upon vesting of a deferred stock unit award granted on April 3, 2024.
• The adjustment also affects the reporting person's vesting schedule and outstanding equity awards.
• The filing shows that Schallenberger now has 378,613 shares beneficially owned following the reported transactions.
• This includes 289,613 shares from the 2023 Equity Incentive Plan and 66,750 shares from the Amended and Restated 2018 Equity Incentive Plan.
• The shares will vest over several years, with the first tranche of 43,367 shares vesting on April 3, 2025.

Sentiment

Score: 7

Explanation: The document is a routine SEC filing related to executive compensation. It is neither particularly positive nor negative, but provides transparency, which is generally viewed favorably.

Positives

• The filing provides transparency regarding the executive's stock ownership and vesting schedule.
• The vesting schedule is spread over multiple years, which may incentivize long-term performance.

Risks

• The vesting of shares is contingent upon the reporting person remaining an employee of Xtant through the applicable vesting dates, which introduces a risk of forfeiture if employment is terminated.

Future Outlook

The shares will vest over the next four years, contingent on the reporting person's continued employment with Xtant Medical Holdings.

Industry Context

This type of filing is common for publicly traded companies and reflects standard practices for executive compensation through equity awards.

Comparison to Industry Standards

• Equity-based compensation is a standard practice across the medical device industry, with companies like Medtronic, Stryker, and Johnson & Johnson also utilizing stock options and restricted stock units as part of their executive compensation packages.
• The vesting schedules described in the document are typical for executive stock awards, often spanning multiple years to align executive interests with long-term company performance.
• The specific number of shares and vesting terms are unique to Xtant Medical Holdings and its compensation policies, but the overall structure is consistent with industry norms.

Stakeholder Impact

• Shareholders will be interested in the details of executive compensation and the alignment of management's interests with long-term company performance.
• Employees may view the vesting schedule as a positive incentive for long-term commitment.

Next Steps

• The shares will vest according to the schedule outlined in the document, contingent on continued employment.

Key Dates

Keywords

SEC Form 4, Xtant Medical Holdings, Stock Awards, Deferred Stock Units, Equity Incentive Plan, Vesting Schedule, Beneficial Ownership, Executive Compensation